Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1080/09537104.2020.1762852

http://scihub22266oqcxt.onion/10.1080/09537104.2020.1762852
suck pdf from google scholar
32397915!ä!32397915
PDF vom PMID32397915  :  Publisher

suck abstract from ncbi

pmid32397915
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Platelet functions and activities as potential hematologic parameters related to Coronavirus Disease 2019 (Covid-19) #MMPMID32397915
  • Salamanna F; Maglio M; Landini MP; Fini M
  • Platelets 2020[Jul]; 31 (5): 627-632 PMID32397915show ga
  • Coronavirus disease 2019 (COVID-19) is a new infectious disease that currently lacks standardized and established laboratory markers to evaluate its severity. In COVID-19 patients, the number of platelets (PLTs) and dynamic changes of PLT-related parameters are currently a concern. The present paper discusses the potential link between PLT parameters and COVID-19. Several studies have identified a link between severe COVID-19 patients and specific coagulation index, in particular, high D-dimer level, prolonged prothrombin time, and low PLT count. These alterations reflect the hypercoagulable state present in severe COVID-19 patients, which could promote microthrombosis in the lungs, as well as in other organs. Further information and more advanced hematological parameters related to PLTs are needed to better estimate this link, also considering COVID-19 patients at different disease stages and stratified in different cohorts based on preexisting co-morbidity, age, and gender. Increasing the understanding of PLT functions in COVID-19 will undoubtedly improve our knowledge on disease pathogenesis, clinical management, and therapeutic options, but could also lead to the development of more precise therapeutic strategies for COVID-19 patients.
  • |*Betacoronavirus[MESH]
  • |*Pandemics[MESH]
  • |Angiotensin-Converting Enzyme 2[MESH]
  • |Anticoagulants/administration & dosage/therapeutic use[MESH]
  • |Biomarkers/blood[MESH]
  • |Blood Platelets/*physiology/ultrastructure[MESH]
  • |COVID-19[MESH]
  • |Cell Adhesion Molecules/metabolism[MESH]
  • |Coronavirus Infections/*blood/complications/pathology[MESH]
  • |Cytokines/metabolism[MESH]
  • |Disseminated Intravascular Coagulation/etiology[MESH]
  • |Drug Interactions[MESH]
  • |Endothelial Cells/pathology[MESH]
  • |Endothelium, Vascular/pathology[MESH]
  • |Fibrin Fibrinogen Degradation Products/analysis[MESH]
  • |Humans[MESH]
  • |Inflammation[MESH]
  • |Lung/pathology[MESH]
  • |Peptidyl-Dipeptidase A/physiology[MESH]
  • |Platelet Count[MESH]
  • |Platelet Function Tests[MESH]
  • |Pneumonia, Viral/*blood/complications/pathology[MESH]
  • |Prothrombin Time[MESH]
  • |Receptors, Virus/physiology[MESH]
  • |Respiratory Distress Syndrome/etiology/prevention & control[MESH]
  • |SARS-CoV-2[MESH]
  • |Severe Acute Respiratory Syndrome/blood/pathology[MESH]
  • |Thrombophilia/blood/drug therapy/*etiology[MESH]
  • |Venous Thrombosis/epidemiology/etiology/pathology/prevention & control[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    627 5.31 2020